Osteoporosis treatment with denosumab in routine clinical practice in Poland
Osteoporosis treatment with denosumab in routine clinical practice in Poland
About this item
Full title
Author / Creator
Publisher
Wydawnictwo Via Medica
Journal title
Language
English
Formats
Publication information
Publisher
Wydawnictwo Via Medica
Subjects
More information
Scope and Contents
Contents
INTRODUCTION: The receptor activator for nuclear factor k B ligand (RANKL) inhibitor denosumab is approved for the treatment of osteoporosis in postmenopausal women and men at increased fracture risk. The objectives were to describe the characteristics of patients with osteoporosis initiating denosumab in Polish clinical practice and their clinical...
Alternative Titles
Full title
Osteoporosis treatment with denosumab in routine clinical practice in Poland
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2835415390
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2835415390
Other Identifiers
ISSN
0423-104X
E-ISSN
2299-8306
DOI
10.5603/EP.a2023.0037
